2023年健康元药业集团股份有限公司中报

Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023 Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023 Important Notice Ⅰ The Board of Directors (the “Board”), the Board of Supervisors and directors, supervisors and senior management of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of the interim report (the “Report”), and that there are no false representations, misleading statements or material omissions contained in the Report, and severally and jointly accept responsibility. Ⅱ All the directors of the Company attended the Board meeting. Ⅲ The interim report of the Company is unaudited. Ⅳ Mr. Zhu Baoguo (朱保国), the person-in-charge of the Company, and Mr. Qiu Qingfeng (邱庆 丰), the person-in-charge of the Company's accounting work and the person-in-charge of the accountingdepartment(theheadoftheaccountingdepartment),declarethattheyherebywarrant the truthfulness, accuracy and completeness of the financial statements contained in the Report. Ⅴ Profit distribution plan or plan for conversion of capital reserve to share capital approved by the Board during the Reporting Period Not applicable VI Risk declaration for the forward-looking statements √Applicable □N/A TheReport containsforward-lookingstatements whichinvolve thefuture plans, development strategies, etc. of the Company, yet do not constitute substantive undertakings of the Company to investors. Investors should exercise caution prior to making investment decisions. VII Whether there is non-operating use of funds by the controlling shareholder and their related parties No VIII Whether there is a violation of the prescribed decision-making procedures to provide external guarantees No IX Whether more than half of directors cannot warrant the truthfulness, accuracy and completeness of the Report disclosed by the Company No X Significant risk warnings Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023 There is no exceptionally significant risk that will have a material impact on the productions and operations of the Company during the Reporting Period. The Company has described various risks related to productions and operations that the Company may face and the corresponding response measures taken. Please refer to “Risks” in Chapter 3 “Management Discussion and Analysis”. XI Others □Applicable √N/A Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023 Table of Contents Financial Highlights...... 5 Chapter 1 Definitions...... 7 Chapter 2 Company Profile and Major Financial Indicators...... 9 Chapter 3 Management Discussion and Analysis ...... 13 Chapter 4 Corporate Governance ...... 49 Chapter 5 Environmental and Corporate Social Responsibility ...... 51 Chapter 6 Major Events...... 85 Chapter 7 Changes in Equity and Shareholders...... 97 Chapter 8 Information on Preferred Shares ...... 101 Chapter 9 Information on Bonds...... 102 Chapter 10 Financial statements...... 103 The Financial Statements signed and sealed by the person-in-charge of the Company, the person-in-charge of the Company's accounting work and the List of documents person-in-charge of the accounting department (the head of the accounting available for inspection department) The originalcopies of all documents and announcements of the Companywhich have been disclosed to the public on the website designated by CSRC (China Securities Regulatory Commission) during the Reporting Period Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023 Financial Highlights Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023 Financial Highlights Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023 Chapter 1 Definitions In this Report, unless the context otherwise requires, the following expressions shall have the following meanings: Definitions of common terms CSRC Refers to China Securities Regulatory Commission SSE Refers to Shanghai Stock Exchange Baiyeyuan or the Refers to Shenzhen Baiyeyuan Investment Co., Ltd. * (深圳市百业源 Controlling Shareholder 投资有限公司) Company or the Refers to Joincare Pharmaceutical Group Industry Co., Ltd. * (健康元 Company 药业集团股份有限公司) GDR Refers to Global Depository Receipts CDE Refers to Center For Drug Evaluation (国家药品监督管理局药品审 评中心) FDA Refers to U.S Food and Drug Administration GMP Refers to Good Manufacturing Practice GSP Refers to Good Supply Practice BE Refers to Bioequivalence MVR Refers to Mechanical Vapor Recompression QC Refers to Quality Control ROI Refers to Return on Investment R&D Refers to Research and Development Livzon Group Refers to Livzon Pharmaceutical Group Inc.* (丽珠医药集团股份有 限公司) Haibin Pharma Refers to Shenzhen Haibin Pharmaceutical Co., Ltd.* (深圳市海滨制 药有限公司) Xinxiang Haibin Refers to Xinxiang Haibin Pharmaceutical Co., Ltd. * (新乡海滨药业 有限公司) Taitai Pharmaceutical Refers to Shenzhen Taitai Pharmaceutical Co., Ltd. * (深圳太太药业 有限公司) Joincare Haibin Refers to Joincare Haibin Pharmaceutical Co., Ltd.* (健康元海滨药业 有限公司) Taitai Genomics Refers to Shenzhen Taitai Genomics Inc. Co., Ltd. * (深圳太太基因 工程有限公司) Jiaozuo Joincare Refers to Jiaozuo Joincare Bio Technological Co., Ltd.* (焦作健康元 生物制品有限公司) Topsino Refers to Topsino Industries Limited * (天诚实业有限公司) Fenglei Electric Power Refers to Shenzhen Fenglei Electric Power Investment Co., Ltd. * (深 圳市风雷电力投资有限公司) Health China Refers to Health Pharmaceutical (China) Co., Ltd. * (健康药业（中 国）有限公司) Shanghai Frontier Refers to Shanghai Frontier Health Pharmaceutical Technology Co., Ltd. * (上海方予健康医药科技有限公司) Joincare Research Refers to Henan Joincare Biomedical Research Institute Co., Ltd.*(河 Institute 南省健康元生物医药研究院有限公司) Livzon MAB Refers to Livzon MABPharm Inc. * (珠海市丽珠单抗生物技术有限 公司) Livzon Diagnostics Refers to Zhuhai Livzon Diagnostics Inc. * (珠海丽珠试剂股份有限 公司) Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023 Livzon Xinbeijiang Refers to Livzon Group Xinbeijiang Pharmaceutical Manufacturing Inc.* (丽珠集团新北江制药股份有限公司) Ningxia Pharmaceutical Refers to Livzon Group (Ningxia) Pharmaceutical Manufacturing Co., Ltd.* (丽珠集团（宁夏）制药有限公司) Gutian Fuxing Refers to Gutian Fuxing Pharmaceutical Co., Ltd. * (古田福兴医药有 限公司) Fuzhou Fuxing Refers to Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd.* (丽 珠集团福州福兴医药有限公司) Livzon Hecheng Refers to Zhuhai FTZ Livzon Hecheng Pharmaceutical Manufacturing Co., Ltd. * (珠海保税区丽珠合成制药有限公司) Livzon Limin Refers to Livzon Group Limin Pharmaceutical Manufacturing Factory * (丽珠集团利民制药厂) Livzon Pharmaceutical Refers to Livzon Group Livzon Pharmaceutical Factory * (丽珠集团 Factory 丽珠制药厂) Shanghai Livzon Refers to Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. * (上海丽珠制药有限公司) Sichuan Guangda Refers to Sichuan Guangda Pharmaceutical Manufacturing Co., Ltd. * (四川光大制药有限公司) Jiaozuo Hecheng Refers to Jiaozuo Livzon Hecheng Pharmaceutical Manufacturing Co., Ltd. * (焦作丽珠合成制药有限公司) Jinguan Electric Power Refers to Jiaozuo Jinguan Jiahua Electric Power Co., Ltd. * (焦作金冠 嘉华电力有限公司) Tianjin Tongrentang Refers to Tianjin Tongrentang Group Co., Ltd. * (天津同仁堂集团股 份有限公司) COVID-19 pandemic or Refers to The outbreak of the disease caused by a new coronavirus pandemic called SARS-CoV-2 Reporting Period Refers to From 1 January 2023 to 30 June 2023 End of the Reporting Refers to 30 June 2023 Period Currency or unit Refers to RMB unless otherwise specified *For identification purpose only Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2023 Chapter 2 Company Profile and Major Financial Indicators I Company profile Chinese name of the Company 健康元药业集团股份有限公司 Abbreviation of the Chinese name 健康元 English name of the Company Joincare Pharmaceutical Group Industry Co., Ltd Abbreviation of the English name Joincare Legal representative of the Company Zhu Baoguo II Contac